CEL-SCI Corp

CVM

8.670USD

-0.250-2.80%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

159 / 506

Overall Ranking

270 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

300.000

Target Price

+3558.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

Overvalued

The company’s latest PE is -0.95, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 280.62K shares, decreasing 30.33% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

The company's current financial score is 5.93, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.93

Change

0



Financials

6.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.98, which is 58.44% below the recent high of -1.55 and -201.02% above the recent low of -2.94.

Score

Industry at a Glance

Previous score

2.80

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 159/506

No Data

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for CEL-SCI Corp is 300.00, with a high of 300.00 and a low of 300.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.75, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 12.05 and the support level at 7.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

-0.02

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

78.44K

-0.74%

BlackRock Institutional Trust Company, N.A.

26.09K

-0.32%

Kersten (Geert R)

43.64K

+5.54%

MAI Capital Management, LLC

17.55K

+229.87%

UBS Financial Services, Inc.

2.94K

+0.62%

Geode Capital Management, L.L.C.

25.10K

+31.51%

Osaic Holdings, Inc.

9.64K

-31.36%

Prichep (Patricia B)

10.75K

+21.11%



1

2



The company’s current risk assessment score is 3.01, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

CEL-SCI Corp

CVM

5.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.14 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.85 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ACADIA Pharmaceuticals Inc

ACAD

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Zymeworks Inc

ZYME

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Veracyte Inc

VCYT

7.59 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment